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Background: While angiogenesis inhibitors represent a viable cancer therapy, there is preclinical and clinical data
to suggest that many tumors develop resistance to such treatments. Moreover, previous studies have revealed a
complex association between autophagy and angiogenesis, and their collective influence on tumorigenesis.
Autophagy has been implicated in cytoprotection and tumor promotion, and as such may represent an alternative
way of targeting apoptosis-resistant cancer cells. This study explored the anti-cancer agent and boswellic acid
analog BA145 as an inducer of autophagy and angiogenesis-mediated cytoprotection of tumor cells.
Methods: Flow cytometry, western blotting, and confocal microscopy were used to investigate the role of BA145
mediated autophagy. ELISA, microvessel sprouting, capillary structure formation, aortic ring and wound healing
assays were performed to determine the relationship between BA145 triggered autophagy and angiogenesis. Flow
cytometery, western blotting, and microscopy were employed to examine the mechanism of BA145 induced cell
death and apoptosis. Live imaging and tumor volume analysis were carried out to evaluate the effect of BA145
triggered autophagy on mouse tumor xenografts.
Results: BA145 induced autophagy in PC-3 cancer cells and HUVECs significantly impeded its negative regulation
on cell proliferation, migration, invasion and tube formation. These effects of BA145 induced autophagy were observed
under both normoxic and hypoxic conditions. However, inhibition of autophagy using either pharmacological
inhibitors or RNA interference enhanced the BA145 mediated death of these cells. Similar observations were
noticed with sunitinib, the anti-angiogenic properties of which were significantly enhanced during combination
treatments with autophagy inhibitors. In mouse tumor xenografts, co-treatment with chloroquinone and BA145
led to a considerable reduction in tumor burden and angiogenesis compared to BA145 alone.
Conclusion: These studies reveal the essential role of BA145 triggered autophagy in the regulation of
angiogenesis and cytoprotection. It also suggests that the combination of the autophagy inhibitors with
chemotherapy or anti-angiogenic agents may be an effective therapeutic approach against cancer.
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Angiogenesis is the physiological process by which new
blood vessels are made from a pre-existing vasculature.
While angiogenesis plays an important role in tissue repair
and in the formation of the placenta during pregnancy, it
is also utilized by malignant cells for their growth and me-
tastasis [1,2]. Suppressing neoangiogenesis in cancer has
been considered an attractive therapeutic option in the era
of target based drug discovery, and several anti-angiogenic
agents are in clinical development for a number of human
malignancies [3,4]. Despite the anticipated benefits, angio-
genesis inhibitors have failed to produce sustained clinical
responses in most patients because of resistance towards
these inhibitors. It has been proposed that the activation
of cytoprotective autophagy accompanies anti-angiogenic
drug resistance [5]. Thus, modulating autophagy may en-
hance the therapeutic activity of anti-angiogenic drugs.
Autophagy removes the unnecessary and dysfunctional
cellular components of the cell via a lysosomal degrad-
ation pathway. It protects cells and promotes survival
during nutrient starvation, infection, or metabolic stress.
There is a complex relationship between autophagy and
angiogenesis in different types of cancers. Some studies
have revealed that autophagy inhibits the angiogenic vas-
culature [6,7], while others have suggested that autophagy
promotes it [8,9].
To better understand the cross-talk between angiogenesis
and autophagy, we focused on the boswellic acid analog
BA145. Our group had recently shown that BA145 is the
most potent anti-cancer analogue of boswellic acid, and in-
duces robust apoptosis in human leukemia HL-60 cells
[10,11]. Other studies have reported the anti-metastatic and
anti-angiogenic properties of boswellic acids [12,13]. Here
we used a well-studied angiogenesis cell model involving
human umbilical vein endothelial cells (HUVECs), the
highly aggressive and metastatic human prostate cancer
cell line PC-3, as well as mouse models of angiogenesis
and cancer to better appreciate the role of autophagy on
cell survival, angiogenesis, and tumor progression. Our
studies indicate that autophagy plays an important role in
cytoprotection by inducing an angiogenic signaling cas-
cade, and that autophagic inhibitors in combination with
cytotoxic agents overcome this cytoprotection, thus re-
vealing a previously unknown utility of boswellic acids in
cancer therapies.
Results
BA145 exhibits antiproliferative and anti-angiogenic
properties
To determine its antiproliferative potential, both PC-3
cells and HUVECs were treated with different concen-
trations of BA145 for 24 and 48 h. Proliferation was
monitored by an MTT assay. BA145 treatment inhibited
the proliferation of PC-3 cells with IC50 values of 40and 18 μM after 24 and 48 h, respectively (Figure 1A).
Similarly, treatment of HUVECs with BA145 indicated
IC50 values of 8 and 4 μM after 24 and 48 h, respect-
ively. FACS analysis of the BA145 treated PC-3 cells and
HUVECs displayed concentration-dependent increases
in a SubG1 apoptotic cell population as well as a loss in
mitochondrial membrane potential (MMP) (Figures 1B
and 1C). The proapoptotic potential of BA145 was fur-
ther confirmed by observing a dose dependent increase
in cleavage of procaspase-3 and PARP-1 in both PC-3
cells and HUVECs (Additional file 1: Figure S1A).
To evaluate the anti-angiogenic potential of BA145
in vivo, a Matrigel plug assay was performed in C57/BL6J
mice and functional blood vessels were quantified spectro-
photometrically by using Drabkin’s reagent. BA145 treat-
ment inhibited VEGF induced blood vessel formation at a
dose of 50 and 100 mg/kg when given subcutaneously for
9 days (Figure 1D). RAD001 (5 mg/kg) was used as a posi-
tive control. Furthermore, in a wound healing assay it was
observed that various concentrations of BA145 inhibited
HUVEC and PC-3 cell migration (Figure 1E).
BA145 inhibits proliferative and angiogenic signaling in
PC-3 cells
VEGF plays a vital role in angiogenesis. VEGF binds to the
cell surface receptors VEGFR-1 and VEGFR-2 and activates
downstream signaling leading to proliferation, migration,
and survival [14]. Hypoxia in tumor tissues induces hyp-
oxia inducible factor-1 (HIF-1) expression, which acts as a
transcription factor of genes involved in hypoxic adapta-
tion, promotion of local neovascularisation, and angiogen-
esis [15,16]. BA145 treatment significantly inhibited VEGF
induced expression of VEGFR-1/R-2 and HIF-1α/1β in
PC-3 cells in a dose dependent manner (Figure 2A). Since
PI3K/Akt plays a vital role in VEGF mediated angiogenesis
[17], we determined whether BA145 was also able to sup-
press the activation of this signaling pathway. Indeed, treat-
ment of PC-3 cells with BA145 led to downregulation of
Akt, Raptor, mTOR, and its downstream substrates p70S6
Kinase and eIF4E (Figure 2A).
BA145 induces robust autophagy in HUVECs and cancer
cells
During autophagy LC3-II is processed from cytosolic
LC3-I and expressed on autophagosome membranes
along with simultaneous degradation of p62. It was ob-
served that various treatments of BA145 in PC-3 cells and
HUVECs for 24 h led to significant increases in LC3-II ex-
pression and p62 degradation compared to untreated cells
(Figure 2B). Time dependent analysis of BA145 treated
PC-3 and HUVECs showed that LC3-II accumulation
took place after 2 h along with attendant degradation of
p62 (Figure 2F). Acridine orange staining of BA145
treated cells also showed increased formation of acidic
Figure 1 (See legend on next page.)
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Figure 1 BA145 exhibits antiproliferative and anti-angiogenic properties. (A) MTT cell viability assay of PC-3 cells and HUVECs treated with
different concentrations of BA145 for 24 and 48 h. (B) FACS analysis of SubG1 cell populations following BA145 treatment of PC-3 cells and
HUVECs at the indicated concentrations for 24 h. (C) Flow cytometric analysis of MMP loss following BA145 treatment of PC-3 cells and HUVECs
at the indicated concentrations for 24 h. (D) Effect of BA145 on VEGF induced angiogenesis in vivo. Six week old C57/BL6J mice were injected
with Matrigel containing 50 and 100 mg/kg BA145 along with 100 ng of VEGF into the ventral area. After 10 days, animals were sacrificed to
remove Matrigel plugs and were photographed. The neovascularization of the Matrigel plugs were quantified spectrophotometrically using
Drabkin’s reagent. (E) VEGF induced chemotactic motility in PC-3 cells and HUVECs following treatment with the indicated concentrations of
BA145 for 10 h. Migrated cells were counted manually, and the percent inhibition of cell migration was calculated as shown. Columns, mean; bars,
SD; with ***p < 0.001, **p < 0.01, *p < 0.05 versus control.
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Figure S1B). Furthermore, BA145 treatment caused a sig-
nificant increase in the punctate distribution of LC3-II in
PC-3 cells, supporting the notion that LC3-II was local-
ized to autophagososmes (Figure 2D). In PC-3 cells, au-
tophagy initiation by BA145 treatment was confirmed by
the increased capture of red fluorescence emitted by the
acridine orange dye through flow cytometry (Figure 2E).
These experiments collectively demonstrated the BA145
dependent induction of autophagic flux in PC-3 cells and
HUVECs. We simultaneously confirmed that BA145 trig-
gers autophagy associated increases in LC3-II expression
and acridine orange positive vesicles among the colorec-
tal cancer cell lines HCT116 and COLO205 (Additional
file 1: Figures S2A and S2B).
Inhibition of autophagy accentuates the cytotoxic
properties of BA145 and sunitinib
External stimuli or chemically induced stress in tumor
cells often triggers autophagy causing cellular dormancy
and developmemt of chemoresistance [18]. Inhibitors of
such prosurvival autophagy can improve the efficacy of
anti-cancer agents when used in combination. BA145 in-
duced autophagy is protective in nature as inhibition of au-
tophagy potentiates BA145 mediated cytotoxicity in PC-3
cells and HUVECs. The combination of BA145 with
various autophagy inhibitors, including ammonium chlor-
ide (an inhibitor of autophagosome-lysosome fusion) and
LY294002 (an inhibitor of the class III PI3kinase activity
required for autophagosome formation), significantly en-
hanced the antiproliferative potential of BA145 in PC-3
cells (Figure 3A) and HUVECs (Additional file 1: Figure
S2C) as evidenced by an increase in SubG1 cell popula-
tions, MMP loss, and cleavage of procaspase-3 and PARP-
1 (Figures 3B, 3C, and 3D, Additional file 1: Figures S2D
and S2E). Surprisingly, the combinatorial effect of 3-MA
with BA145 did not show any significant alteration on cell
survival, though the cleavage of caspase-3 and PARP-1 was
considerably increased (Figure 3). To further explore the
cytoprotective role of autophagy, we tried to inhibit the
expression of key autophagy mediator LC3 in PC-3 cells
through siRNA. LC3 silencing promoted the apoptotic ef-
fect of BA145 as evidenced by increased procaspase-3 and
PARP-1 cleavage when compared to a scrambled siRNAcontrol (Figure 3E). In order to generalize our findings
with other anti-angiogenic agents, we treated PC-3 cells
and HUVECs with sunitinib. It was observed that suniti-
nib treatment decreased cell viability, and simultaneously
induced autophagy (Additional file 1: Figures S3A, S3B,
and S3C). Moreover, inhibition of autophagy with ammo-
nium chloride and bafilomycin greatly enhanced sunitinib
induced cytotoxicity. Note that all the pharmacological
inhibitors of autophagy were used at noncytotoxic
concentrations during these experiments (Figure 3 and
Additional file 1: Figure S3).
BA145 has diverse effects on autophagy among different
cancer cell lines
In the colorectal cancer cell lines HCT116 and COLO205,
autophagy induced by BA145 is cytoprotective in nature as
co-treatment of BA145 with autophagic inhibitors potenti-
ated its cytotoxicity (Additional file 1: Figures S4A and
S4B). This was also true in the MCF-7 breast cancer cell
line where autophagy inhibition with LY294002 signifi-
cantly enhanced BA145 mediated cytotoxicity (Additional
file 1: Figures S4D and S4E). In contrast, MDA-MB-231
breast cancer cells respond to LY294002 pre-treatment
with decreased cytotoxic effects. In the pancreatic cancer
cell lines Mia PaCa-2 and PANC-1, co-treatment of BA145
and LY294002 did not show any significant effect on its
cytotoxicity. However, LY294002 further enhanced LC3-II
accumulation in BA145 treated Mia PaCa-2 cells. More-
over, LY294002 co-treatment in SH-SY5Y neuroblastoma
cells was found to enhance the antiproliferative effect of
BA145 (Additional file 1: Figures S4D and S4E). Thus,
while the impact of BA145 on autophagy can vary
among different cancer cell lines, cancers of widely dif-
ferent origins may also respond similarly to BA145 and
thereby be favorable targets for combinatorial treatment
with autophagic inhibitors.
Autophagy inhibition potentiates the anti-angiogenic
signaling effects of BA145 under both normoxic and
hypoxic conditions
One of the limitations in anti-angiogenic therapies is the
creation of hypoxic tumor microenvironments that favor
cytoprotective autophagy [19]. To explore the role of
autophagy in promoting angiogenesis, we treated PC-3
Figure 2 (See legend on next page.)
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Figure 2 BA145 triggers autophagy and suppresses VEGFR signaling in cancer cells. (A) Western blot analysis of the indicated proteins in
VEGF activated PC-3 cells with or without BA145 treatment for 24 h. (B) Western blot analysis of the expression of the autophagy marker proteins
LC3 and p62 in BA145 treated PC-3 cells and HUVECs after 24 h. (C) Detection of acidic autophagic vesicles in PC-3 cells and HUVECs. After
24 h treatment with BA145, cells were stained with acridine orange (1 μg/ml) in serum free media for 15 min and fluorescent micrographs were
obtained by microscopy. Autophagy is indicated by the red fluorescence while the untreated control cells are green. (D) Detection of LC3-II
protein in PC-3 cells by immunofluorescent microscopy. (E) Quantification of acridine orange positive cells by flow cytometry. PC-3 cells were
treated with BA145 at the indicated concentrations for 24 h, stained with acridine orange (1 μg/ml) for 15 min, and analyzed with the FL3-H (red
color intensity) and FL1-H (green color intensity) channels of the flow cytometer. (F) Time dependent accumulation of LC3-II and loss of p62 in
BA145 treated PC-3 cells and HUVECs.
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co-treatment of BA145 with ammonium chloride, 3-MA,
or LY294002 accentuated the anti-angiogenic properties
of BA145 in PC-3 cells. Autophagy inhibitors augmented
the inhibition of VEGFR-1/R-2 by BA145, and also aug-
mented the inhibition of downstream signaling molecules
like HIF-1α/1β, Src, and FAK (Figure 4A). This wasFigure 3 Effect of autophagic inhibitors on the antiproliferative prope
BA145 (30 μM) and/or the autophagy inhibitors ammonium chloride (10 m
assessed by an MTT assay. (B, C) Analysis of SubG1 cell populations and M
autophagy inhibitors for 1 h followed by addition of BA145 (30 μM) for the
and MMP loss, respectively using flow cytometry. (D) Effect of autophagic
(30 μM) treated PC-3 cells after 24 h. (E) Effect of BA145 on procaspase-3 adespite the lack of any significant effect of autophagy in-
hibitors alone on VEGF signaling in PC-3 cells (Additional
file 1: Figure S5A). Silencing of the autophagic gene LC3
also accentuated the anti-angiogenic effects of BA145 in
PC-3 and HUVECs (Figure 4B). In contrast, the addition
of VEGF (20 ng/ml) to BA145 treated PC-3 cells increased
the expression of LC3-II as compared to BA145 alone,rties of BA145 in PC-3 cells. (A) PC-3 cells were co-treated with
M), 3-MA (5 mM), or LY294002 (20 μM) for 24 h. Cell viability was
MP loss in BA145 treated PC-3 cells. Cells were pretreated with
next 24 h. PI and Rh-123 dyes were used for the analysis of cell cycle
inhibitors on the cleavage of procaspase-3 and PARP-1 in BA145
nd PARP-1 cleavage in LC3 silenced cells.
Figure 4 Autophagy inhibition potentiates the anti-angiogenic effects of BA145. (A) PC-3 cells were treated with BA145 (30 μM) along with
autophagic inhibitors for 16 h. Whole cell protein lysates were prepared for western blotting, and the detection of the indicated proteins. (B) LC3
specific siRNA were used to silence the expression of LC3 in PC-3 cells and HUVECs that were further treated with BA145 for 12 h. Protein lysates
were analyzed by western blotting for the indicated proteins. In the case of HUVECs, prior treatment of VEGF (20 ng/ml) for about 40 min was
given before the addition of BA145 (7 μM). For HIF-1α expression in PC-3 cells, VEGF was added 30 min before the BA145 treatment as PC-3 cells
have less endogenous HIF-1α expression. (C) Effect of BA145 on VEGF production in PC-3 cells. Cells were seeded in 6 well plates, grown to 90%
confluency, and then exchanged with fresh media containing BA145 for 16 h. Secreted VEGF in the culture media as well as intracellular VEGF
were measured by ELISA and western blot, respectively. Columns, mean; bars, SD; with ***p < 0.001, **p < 0.01, *p < 0.05 versus control. (D) Effect
of autophagic inhibitors on VEGF production in BA145 treated PC-3 cells under hypoxic and normoxic conditions. Hypoxia was created by
treating cells with 100 μM cobalt chloride (CoCl2) for 24 h. After incubation, the media was replaced and cells were treated with BA145 (30 μM)
and autophagic inhibitors for the next 16 h. Extracellular VEGF in the media was measured by ELISA. Columns, mean; bars, SD; with **p < 0.01
versus BA145 alone. (E) Western blot analysis of the indicated proteins following treatment of PC-3 cells with BA145 and autophagy inhibitors
under normoxic and hypoxic conditions.
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population, and in procaspae-3 and PARP-1 cleavage
(Additional file 1: Figures S5B, S5C, and S5D).
To generalize our findings with other anti-angiogenic
agents, we found that the autophagy triggered by suni-
tinib treatment of PC-3 cells was accompanied by
increased expression of VEGFR-2 and HIF-1α. However,
co-treatment of sunitinib with ammonium chloridesignificantly downregulated the increased expression of
these proteins and further potentiated the inhibitory effect
of sunitinib on HIF-1β expression as well (Additional
file 1: Figure S6).
In order to simulate actual tumor conditions, we next
determined the consequences of BA145 mediated autoph-
agy under hypoxic microenvironments. Cobalt chloride
was added to the media of PC-3 cells to create hypoxic
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BA145 in combination with inhibitors of autophagy. As
shown in Figure 4C, BA145 inhibited cellular and se-
creted VEGF expression in PC-3 cells. This was further
potentiated by co-treatment with autophagy inhibitors
(Figure 4D). The switching of normoxic to hypoxic con-
ditions in cancers leads to transcriptional activation of
the HIF-1 gene, which is responsible for the induction
of genes that adapt cancer cells under oxygen starved
conditions [20]. PC-3 cells produce low levels of VEGF
and HIF-1α proteins under normoxia, while the expres-
sion of these proteins increases under hypoxic conditions
(Figure 4E). The treatment of PC-3 cells with BA145 inhib-
ited HIF-1α/1β expression under hypoxic conditions and
co-treatment with autophagy inhibitors further augmented
this effect. Moreover, the effect of autophagy inhibition was
also observed on the expression of Signal transducer and
activation of transcription-3 (Stat-3), the constitutive activa-
tion of which enhances HIF-1α expression and triggers
glycolytic metabolism via the Warburg effect [21,22]. Our
results thus demonstrate that autophagy inhibition in
BA145 treated PC-3 cells is able to block this Stat-3 ac-
tivation under hypoxic conditions (Figure 4E).
Autophagy inhibition accentuates the inhibitory effects of
BA145 on angiogenesis as well as on tumor cell colony
formation
We used ex vivo and in vitro models to explore the role of
BA145 triggered autophagy in the regulation of angiogen-
esis. First, we found in an aortic ring assay that autophagy
inhibitors enhanced the BA145 mediated suppression of
microvessel sprouting (Figures 5A and 5C). Secondly, in a
capillary tube formation assay, it was observed that BA145
abolished VEGF induced tube formation by HUVEC
cultures and co-treatment with autophagy inhibitors in-
tensified this effect (Figures 5B and 5C). And thirdly, in a
wound healing cell assay, it was demonstrated that the
effect of BA145 in the inhibition of VEGF induced
HUVECs migration was potentiated by autophagy in-
hibitors (Additional file 1: Figure S7). BA145 treatment
also decreased the colony forming ability of PC-3 cells,
and the numbers of colonies were significantly decreased
during the combinatorial treatment with ammonium
chloride, LY294002, or 3-MA (Figure 5D). Importantly, in-
dividual treatments with autophagy inhibitors showed no
effect on colony formation (Additional file 1: Figure S8A).
Autophagy inhibition promotes the anti-angiogenic
effects of BA145 in vivo
Based on the previously described in vitro experiments,
we next wanted to determine whether a similar role exists
for autophagy inhibitors in BA145 regulation of angiogen-
esis in vivo using the Matrigel plug assay. As shown in
Figure 6A, Matrigel plugs containing VEGF are dark redin color due to the formation of a functional vasculature.
As expected, treatment with BA145 inhibited angiogen-
esis, as indicated by the faint color of the Matrigel plugs.
Chloroquinone (CQ), an antimalarial drug is known to
inhibit autophagy by preventing the acidification of ly-
sosomes, which itself impairs the activity of lysosomal
proteases and hence the autophagic degradation process
[23]. Co-treatment with CQ and BA145 was able to prom-
inently block Matrigel vasculature formation beyond that
of BA145 alone (Figure 6A). H&E staining of the formed
vasculature in the Matrigel plugs further confirmed that
autophagy inhibition by CQ greatly enhanced the anti-
angiogenic activity of BA145 (Figures 6B and C).
Autophagy inhibitors potentiate the antitumor effect of
BA145
Given the success of using CQ to augment the anti-
angiogenic properties of BA145, we next determined
whether CQ could similarly augment the therapeutic effi-
cacy of BA145 against aggressive PC-3 M-luc2 xenografts
in NOD.SCID mice. It was observed that the mean tumor
volume increased in control mice from 69.0 ± 18.5 mm3
on day 18 to 984.16 ± 100.62 mm3 on day 46. This was
compared to the 28 day treatment with BA145 that re-
sulted in a tumor volume increase of 60.0 ± 14.68 mm3 to
710 ± 77.48 mm3 (28% inhibition), and the combination
treatment of BA145 and CQ that resulted in a tumor vol-
ume increase of 64.0 ± 13.7 mm3 to 410.8 ± 36 mm3 (58%
inhibiton) (Figures 6D and E). Additionally, the average
weight of the excised tumors was 0.85 ± 0.15 g in control
mice, 0.65 ± 0.14 g in BA145 treated mice, and 0.22 ± 0.1 g
in mice treated with both BA145 and CQ (Figure 6E).
Interestingly, it was observed that BA145 and CQ co-
treatment did not have any significant effect on the body
weight of mice (Additional file 1: Figure S8B). Flutamide,
an anti-androgen used in the treatment of prostate can-
cers, was used as a positive control group during the ex-
periment, while CQ at a dose of 50 mg/kg was non-toxic
to mice (Figure 6D).
Inhibition of autophagy enhances the suppression of
pro-angiogenesis factors and associated tumor burden in
BA145 treated mice
To explore the mechanism by which CQ improved the
anti-tumor efficacy of BA145, we examined the changes
in angiogenic and apoptotic signals in tumor tissues.
Hence, tumor tissues were harvested and lysed in order
to monitor the expression of angiogenic and apoptotic
factors by western blot analysis. As shown in Figure 6F,
BA145 inhibited the activation of VEGFR-2/HIF-1α/
HIF-1β in prostate xenografts while the addition of CQ
potentiated this effect. Moreover, co-treatment with CQ
and BA145 enhanced the cleavage of procaspase-3 and
PARP-1 in tumor tissues.
Figure 5 Autophagy inhibition significantly enhances BA145 mediated anti-angiogenic activity. (A) Aortic segments were isolated from
Sprague-Dawley rats and placed in Matrigel-covered wells. BA145 (10 μM) was added to the wells along with ammonium chloride (N; 10 mM),
3-MA (5 mM), or LY294002 (10 μM) for 4 days. Microvessel sprouting was quantitated with Image J software. (B) Effect of autophagy inhibition
on BA145 mediated suppression of VEGF-induced tube formation. HUVECs were seeded in 24-well plates coated with Matrigel and co-treated
with BA145 (10 μM) and autophagy inhibitors for 8 h. Cells were fixed and tubular structures were photographed. (C) Percentage inhibition of
microvessel sprouting and tube formation of endothelial cells by BA145 along with autophagy inhibitors. (D) Colony formation assay of PC-3 cells.
Cells were treated with BA145 (30 μM) along with the indicated autophagy inhibitors for 24 h. Cells were trypsinized and 1000 viable cells were
seeded in 60 mm dishes. Cells were allowed to form colonies for 15 days, stained with 1% crystal violet, and counted manually. Columns, mean;
bars, SD; with ***p < 0.001, **p < 0.01, *p < 0.05 versus BA145 alone.
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Over the past decade, our understanding of angiogenesis
and its role in cancer has increased to a great extent lead-
ing to the approval of anti-angiogenic drugs for the treat-
ment of cancer [1,4]. However, many tumors develop drug
resistance with progression of the disease occurring afterjust a few months of treatment [24,25]. The molecular
mechanism of resistance is not well understood as there
are many factors which may play role in this process. Sev-
eral studies have demonstrated that autophagy plays a cru-
cial role in cell survival and resistance to external stress.
Regarding tumors, there are several contentious reports
Figure 6 (See legend on next page.)
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Figure 6 Autophagy inhibition potentiates the anti-angiogenic effects of BA145 in vivo. (A) Effect of BA145 and CQ on VEGF induced
angiogenesis. Six weeks old C57BL/6 J mice were injected with Matrigel containing BA145 (50 mg/kg), CQ (50 mg/kg), or both BA145 and CQ
along with VEGF (150 ng) into the ventral area (6 mice per group). Matrigel plugs were monitored 10 days later. (B) Matrigel plugs were fixed,
sectioned, and stained with H&E. (C) Neovascularization of Matrigel plugs were quantified with Drabkin’s reagent using a spectrophometer.
(D) Effect of BA145 and CQ on tumor growth in vivo. PC-3 M-luc2 cells implanted into NOD.SCID mice were treated with vehicle, BA145 (75
mg/kg), BA145 (75 mg/kg) plus CQ (50 mg/kg), positive control flutamide (25 mg/kg), and CQ (50 mg/kg) on alternate days for 28 days. Tumor
volumes are reported as mean ± SE. (E) Representative pictures of excised tumors and their mass. (F) Western blot analysis of the indicated
proteins in tumor tissues. β actin was used as loading control. Columns, mean; bars, SD; with ***p < 0.001 versus BA145 alone.
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cer cell death. Although some studies have shown that the
autophagy is a different form of cell death [26,27], others
have reported that it is a protective mechanism against
chemotherapy related toxicity [28,29]. In our studies we
used the natural compound derivative BA145, a robust
autophagy inducer, to investigate the complex associ-
ation between autophagy, angiogenesis, and cell fate.
We are reporting for the first time that BA145 induced
autophagy in cancer cells is cytoprotective in nature,
and confers protection against the cytotoxic and anti-
angiogenic properties of BA145. Using different in vitro,
ex vivo and experimental mouse models, we have shown
that BA145 triggered autophagy promotes cytoprotection
and angiogenesis. We further show that combinatorial
treatments involving BA145 and autophagy inhibitors can
be exploited for enhanced tumor cytotoxicity.
BA145 triggered the apoptotic cell death of PC-3 cells
and HUVECs based on an observed increase in SubG1
cell populations, a loss in MMP, PARP-1 cleavage, and acti-
vation of caspases. BA145 also exhibited anti-angiogenic
properties by suppressing VEGF signaling both in vitro and
in vivo. This included the expression of the pro-angiogenic
drivers VEGFR-1 and VEGFR-2 as well as several down-
stream signaling components like HIF-1α, HIF-1β, Src, and
FAK. It was further observed that BA145 triggered robust
autophagy in PC-3 cells and HUVECs as observed by
microscopy, flow cytometry, and the expression of key au-
tophagy proteins. While the role of autophagy in cell death
and survival is controversial, our findings conducted in
PC-3 cells and HUVECs demonstrated that BA145
induced autophagy is cytoprotective and its inhibition
through siRNA or pharmacological inhibitors (e.g. am-
monium chloride, 3-MA, or LY294002) augmented the
anti-angiogenic and proapoptotic effects of BA145. We
further demonstrated that the consequences of BA145
triggered autophagy on cell fate was cell line specific. In
the case of HCT116 and COLO205 colon cancer cells,
MCF-7 breast cancer cells, and SH-SY5Y neuroblastoma
cells, BA145 induced autophagy remained cytoprotective
in nature and cytotoxicity was enhanced by autophagy in-
hibitors. However, in PANC-1 and Mia PaCa-2 cancer
cells, autophagy inhibition did not show any significant ef-
fect on BA145 mediated cytotoxicity. In MDA-MB-231breast cancer cells, autophagy inhibition by LY294002 ac-
tually decreased BA145 induced cytotoxicity.
Inhibition of autophagy in BA145 treated PC-3 cells
enabled significant downregulation of VEGF induced
angiogenic signaling compared to BA145 alone. Further-
more, the expression levels of intracellular and extracel-
lular VEGF in PC-3 cells was also diminished. Stat-3 is a
point of convergence for many signaling pathways in-
volved in cell proliferation, tumor growth, and angiogen-
esis [30], and its expression correlates with the
expression of VEGF in human cancer cell lines [31]. Ac-
tivated Stat-3 also mediates the up-regulation of HIF-1α
by increasing its stability and transcriptional activity
[31]. Interestingly, it was also observed that under condi-
tions of hypoxia, the expression of HIF-1, Stat-3 and
VEGF proteins were significantly reduced by combina-
torial treatments of BA145 and autophagic inhibitors as
compared to BA145 alone. This indicates that autophagy
can promote the expression of these pro-survival and
pro-angiogenic proteins. The addition of autophagy in-
hibitors significantly enhanced the anti-angiogenic ef-
fects of BA145 as evidenced by reduced capillary like
structures, microvessel sprouting and migration in
HUVECs. Autophagy inhibition in PC-3 cells enhanced
the inhibitory effect of BA145 on colony formation. In
mouse models, autophagy inhibition by CQ cooperated
with BA145 to completely block vascular formation.
And in highly aggressive prostate cancer xenografts in
NOD-SCID mice, treatment with BA145 and CQ sup-
pressed tumor growth by 58%, an over 2-fold enhance-
ment relative to BA145 treatment alone. Expression
analysis of tumor samples for key angiogenic and au-
tophagy factors revealed that autophagy inhibition by
CQ significantly potentiated the negative regulation of
BA145 on VEGFR-2, HIF-1α, and HIF-1β, and increased
pro-apototic signals. Similarly, inhibiting autophagy in
sunitinib treated PC-3 cells and HUVECs greatly en-
hanced the antiproliferative activity of sunitinib against
cancer cells. Consistent with previous studies, it was
found that sunitinib treatment increased VEGFR-2 and
HIF-1α expression in PC-3 cells [32-34]. This enhanced
expression of HIF-1α may be due to the creation of hyp-
oxia, which plays a critical role in the development of an-
giogenic drug resistance. Our results further demonstrated
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in sunitinib treated PC-3 cells led to the supression of
angiogenesis as evidenced by the significant decrease in
VEGFR-2, HIF-1α, and HIF-1β expression.
Conclusion
Development of cellular resistance against available anti-
cancer or anti-angiogenic agents is a major challenge in
the successful treatment of this disease. Understanding
the basis of this resistance is critical to the development
of novel and effective therapies. During this study, we
found that autophagy is one of the mechanisms by which
cancer cells protect themselves against cytotoxic or anti-
angiogenic agents. Our results showed that the autophagy
triggered by the anti-cancer agents BA145 or sunitinib
was not only initiated as a survival mechanism, but also
promoted angiogenesis. Together these findings suggest
that it is important to understand the role of autophagy
on cell fate in various cancers triggered by potential anti-
cancer agents. A combination of autophagy inhibitors can
be useful in enhancing the therapeutic efficacy of these
agents and should be further tested in clinical settings.
Methods
Reagents and Antibodies
RPMI-1640, MEM, propidium iodide (PI), rhodamine-123
(Rh-123), acridine orange, 3-(4, 5- dimethylthiazole-2-yl)-
2,5 diphenyltetrazolium bromide (MTT), phenylmetha-
nesulfonyl fluoride (PMSF), 3-methyl adenine (3-MA),
chloroquinone (CQ), ammonium chloride, bafilomycin,
cobalt chloride, sodium fluoride, kanamycin, strepto-
mycin, fetal bovine serum (FBS), β-mercaptoethanol,
and human VEGF were purchased from Sigma-Aldrich,
Missouri, USA. Growth factor reduced Matrigel were
from BD Biosciences, New Jersey, USA. Antibodies for
casapse-8, caspase-9, caspase-3, PARP-1, and β-Actin were
from Santa Cruz Biotechnology, Texas, USA. All other
antibodies and LY294002 were purchased from Cell Sig-
naling Technology, Massachusetts, USA. Electrophoresis
reagents, reagents for protein estimation, and protein mo-
lecular weight markers were from Bio-Rad Laboratories,
California, USA.
Cell Culture and Treatments
The human prostate cancer cell line PC-3, the colorectal
carcinoma cell lines HCT116 and COLO205, the human
breast cancer cell lines MCF-7 and MDA-MB-231, the hu-
man pancreatic cancer cell lines Panc-1 and Mia PaCa-2,
the human neuroblastoma cell line SH-SY5Y and primary
human umbilical vein endothelial cells (HUVECs) were
purchased from ECACC, England. Cancer cells were grown
in RPMI/MEM/McCOY/DMEM growth media containing
10% FBS, 100U penicillin G, and 100 μg streptomycin per
ml. HUVECs were grown in EndoGRO-LS complete mediafrom Millipore. Cells were grown in a CO2 incubator
(Thermocon Electron Corporation, Texas, USA) at 37°C
with 95% humidity. BA145, bafilomycin, and LY294002
were dissolved in DMSO (final concentration <0.2%);
ammonium chloride, CQ, and 3-MA were solubilized in
Milli-Q water.
Cell Proliferation Assay
Cells were seeded in 96 well plates. When at 70-75%
confluency, cells were treated with different concentra-
tions of BA145 for 24 and 48 h. All inhibitors used in
the experiment were added 1 h before the treatment of
BA145. Cell proliferation was assessed by using an MTT
assay as previously described [35].
Mitochondrial Membrane Potential (MMP) Loss
Cells were treated with or without inhibitors at different
concentrations for 24 h. Mitochondrial membrane po-
tential loss (Ψmt) was analyzed by using the fluorescent
probe rhodamine 123 as previously described [11].
Wound Healing Migration Assay
Cells were seeded in 6 well plates. When at 80% con-
fluency, a micro tip was used to draw a scratch across the
center of the culture plate to produce a clean wound area.
Cells were incubated with BA145 for 8-10 h, and cell mi-
gration was examined under the microscope (Olympus
Imaging) by manual counting.
Colony Formation Assay
Cells were treated with BA145 in the presence or ab-
sence of autophagic inhibitors at different concentrations
for 24 h. Cells were then trypsinized, viable cells were
counted, and 1000 cells were seeded in 60 mm dishes
for 15 days to determine the effect of these compounds on
clonogenic survival. The colonies were fixed in 4% formal-
dehyde for 15-20 min, stained with 1% crystal violet, and
the colonies counted.
Enzyme-linked Immunosorbent Assay (ELISA) for VEGF
PC-3 cells were seeded in 60 mm dishes. When at 90-95%
confluency, cells were treated with BA145 in the presence
or absence of autophagic inhibitors and incubated under
hypoxic or normoxic conditions for 16 h. Supernatants
from the media were collected and the VEGF concentra-
tion was determined according to manufacturer guidelines
using a VEGF ELISA kit from R&D Systems (#DVE00),
Minnesota, USA.
Capillary-like Tube Formation Assay
A tube formation assay was performed by using an in vitro
angiogenesis assay kit (Millipore, #ECM 625) according to
manufacturer guidelines. Briefly, the extracellular matrix
was diluted with diluents buffer before use at 4°C, and
Pathania et al. Molecular Cancer 2015, 14:6 Page 13 of 15
http://www.molecular-cancer.com/content/14/1/650 μl of this solution was transferred to each well of a pre-
cooled 96 well plate. The plate was placed in an incubator
at 37°C for at least 1 h to allow the solidification of the
matrix solution. HUVECs were trypsinized, and 5000–
8000 cells were seeded in each matrix coated well, followed
by overnight incubation at 37°C. Cells were treated with
BA145 and autophagic inhibitors for 10 h. Tube formation
was observed under the light microscope at 10X magnifi-
cation equipped with a digital camera (Olympus Imaging),
and were counted manually.
Aortic Ring Assay
A rat aortic ring assay was performed as previously de-
scribed [36]. Briefly, Sprague Dawley rats were obtained
from the central animal facility of the institute. Rats
were sacrificed by cervical dislocation and aortas were
isolated, precleaned from periadventitial fat, and cut into
rings at 1 to 1.5 mm in circumference under aseptic condi-
tions. The aortic rings were embedded in Matrigel with or
without VEGF (20 ng/ml), followed by treatment with
BA145 (10 μM) alone or in combination with LY294002
(10 μM), 3-MA (5 mM) and ammonium chloride (10 mM)
for 4 days. Microvessel sprouts were fixed, photographed
using an Olympus IX70 inverted microscope, and counted
using Image J software [36].
In Vivo Angiogenesis Assay
A Matrigel plug assay was performed as previously de-
scribed [37]. Briefly, 0.5 ml ice cold Matrigel (BD Biosci-
ences) was injected subcutaneously along with VEGF-A
(150 ng/mL), BA145 (50 mg/Kg body weight (BW), and/
or CQ (50 mg/kg BW) into C57/BL6J male mice (20-
25 g, 4-6 weeks old). After 10 days, mice were sacrificed
in order to remove the Matrigel plugs and photographs
were taken. The neovascularization of the Matrigel plugs
was quantified using Drabkin’s reagent and the absorb-
ance was measured spectrophotometerically at 540 nm
in order to estimate hemoglobin (Hb) where Hb (g/dl) =
absorbance of sample/absorbance of standard × concen-
tration of standard. All mice were obtained from the cen-
tral animal facility of the institute. Mice were housed and
cared under standard conditions and animal studies were
performed according to experimental protocols approved
by the Institutional Animal Ethics Committee (IAEC).
Tumor Studies
The antitumor efficacy of BA145 and the autophagic in-
hibitor CQ were examined against human prostate can-
cer xenografts in mice. Male NOD.SCID mice (18-23 g)
were procured from the animal facility of the institute
and were housed in a sterile microenvironment. The
number of animals and the protocols used in this study
were approved by the IAEC. PC-3 M-luc2 cells (3 × 106)
were suspended in PBS, mixed with an equal volume ofMatrigel, and injected subcutaneously into the right flanks
of each animal on day 0. Tumor growth was monitored on
every alternate day and animals bearing 50-100 mg tumor
mass were selected for the experiment on the staging day
(day 18). Mice were randomly distributed into 5 different
groups with 6 mice in each group. Group I was adminis-
tered 0.2 ml normal saline (i.p.), and served as an untreated
control. Group II was treated with BA145 (75 mg/kg i.p.)
on every alternate day. Group III was administered BA145
(75 mg/kg i.p.) and CQ (50 mg/kg i.p.) on every alternate
day. Group IV was administered flutamide (25 mg/kg p.o.),
and served as a positive control. Group V was adminis-
tered with CQ (50 mg/kg i.p.) on every alternate day. Tu-
mors volumes were calculated as described earlier [38]. On
day 46, all animals were sacrificed and tumors were ex-
cised. Cell lysates were prepared from the harvested tu-
mors using RIPA buffer for western blotting.
Immunofluorescence and Confocal Microscopy
PC-3 cells were grown on coverslips and treated with
BA145 at different concentrations for 24 h. Cells were
fixed, stained, and analyzed under the fluorescent micro-
scope as previously described [11].
Preparation of Cell Lysates and Western Blot Analysis
The preparation of cell lysates and protein specific im-
munoblotting was performed as previously described [11].
Statistical Analysis
Data are presented as means of three similar experiments
and the error bars represent the standard deviation (SD)
between the experiments. Statistical analysis was done
using the Bonferroni method and a p value <0.05 was con-
sidered to be significant (***p < 0.001, **p < 0.01, *p < 0.05).
Additional file
Additional file 1: Figure S1. BA145 induced apoptosis and autophagy
in PC-3 and HUVECs. Figure S2: Role of BA145 induced autophagy in
cancer cell lines. Figure S3: Inhibition of autophagy enhanced sunitinib
mediated cytotoxicity in PC-3 cells and HUVECs. Figure S4: Effect of
autophagy inhibitors on BA145 mediated cytotoxicity in cancer cell lines.
Figure S5 (A) Effect of ammonium chloride (10 mM), 3-MA (5 mM), or
LY294002 (20 μM) on angiogenic signaling proteins in PC-3 cells. Cells
were treated with these inhibitors for 16 h and protein lysates were
prepared for western blot analysis of the indicated proteins. (B) VEGF
addition increases LC3-II expression in BA145 treated PC-3 cells. Cells
were treated with BA145 (30 μM) in the presence or absence of VEGF
(20 ng/ml) for 24 h. Lysates were prepared and western blotting of the
indicated proteins was performed. (C and D) MTT assay and SubG1 cell
cycle analysis of BA145 treated PC-3 cells in the presence or absence
of VEGF. Columns, mean; bars, SD; with *p < 0.05 versus BA145 alone.
Figure S6: Effect of ammonium chloride on VEGFR-2, HIF-1α and HIF-1β
expression in sunitinib treated PC-3 cells. Figure S7: Combinatorial effects
of BA145 and autophagy inhibitors on VEGF induced chemotaxis of
endothelial cells. Figure S8 (A) Colony formation in ammonium chloride
(10 mM), 3-MA (5 mM), or LY294002 (20 μM) treated PC-3 cells after 24 h.
Cells were trypsinized and 1000 viable cells were seeded in 60 mm
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http://www.molecular-cancer.com/content/14/1/6dishes. Cells were allowed to form colonies for 15 days after which
colonies were stained with 1% crystal violet and photographed. (B) Body
weight changes in mice treated with BA145, CQ, and/or flutamide (Flt25).
There was no significant difference in body weight between the treated
groups and the control group in this study.
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